The Accretion Nutraveda IPO will raise up to ₹25 crore from the market. It comprises a fresh issue of 19,20,000 equity shares with a face value of ₹10 each. The subscription window for the IPO opens on January 27, 2026. The subscription window ends on January 30, 2026. The allotment of shares is scheduled for February 2, 2026. The listing on BSE SME is planned for February 4, 2026.
Each lot contains 1,000 shares, and the issue is priced in the range of ₹122 to ₹129. Retail investors need to apply for at least 2 lots, requiring an investment of ₹2,58,000. The sNII investors will have an outlay of ₹3,87,000 for three lots. For the bNII category, bidding starts at 8 lots, making their investment ₹10,32,000.
Accretion Nutraveda IPO Details
An overview of the IPO’s essential information is provided in the table below:
| Particulars | Details |
| IPO Opens | January 27, 2026 |
| IPO Closes | January 30, 2026 |
| Issue Type | Book-built IPO |
| Face value | ₹10 per share |
| Price Band | ₹122 to ₹129 |
| Issue price | |
| IPO Lot Size | 1,000 Shares |
| Listing at | BSE SME |
| Offer for Sale | |
| Fresh Issue | 19,20,000 shares (₹25 Crore) |
| Total Issue | 19,20,000 shares (₹25 Crore) |
| Minimum Investment | ₹2,58,000 |
Accretion Nutraveda IPO Timeline
The IPO will follow the given timeline:
| Particulars | Details |
| IPO Opens | January 27, 2026 |
| IPO Closes | January 30, 2026 |
| Allotment Scheduled | February 2, 2026 |
| Refund Initiation | February 3, 2026 |
| Shares Credit to Demat | February 3, 2026 |
| Tentative Listing Date | February 4, 2026 |
| Deadline for UPI mandate | – |
Accretion Nutraveda Key Performance Indicator
Given below are the Accretion Nutraveda’s Key Performance Indicators (KPIs):
| KPIs | FY 2023 | FY 2024 | FY 2025 |
| ROE (%) | 228.56 | 121.94 | 81.22 |
| ROCE (%) | 12.51 | 28.98 | 36.98 |
| Debt Equity (times) | 7.50 | 2.00 | 0.72 |
| RoNW (%) | 106.66 | 75.75 | 48.85 |
| PAT Margin (%) | 9.67 | 16.42 | 16.33 |
| EBITDA margin (%) | 20.36 | 24.10 | 22.79 |
| Price Book Value | – | – | 8.76 |
Accretion Nutraveda Financials
The key financial figures of Accretion Nutraveda are provided below:
| Particulars (in ₹ lakh) | 2023 | 2024 | 2025 |
| Revenue | 307.14 | 519.68 | 1,605.55 |
| Total Asset | 406.02 | 463.88 | 1,086.22 |
| Profit | 28.06 | 82.19 | 261.28 |
Subscription Status of the Accretion Nutraveda IPO
The following table presents Accretion Nutraveda IPO’s subscription status:
| Day | NII | Individual Investor | Total |
| Day 1 | |||
| Day 2 | |||
| Day 3 |
Accretion Nutraveda IPO Grey Market Premium Today
The Accretion Nutraveda IPO is quoting a grey market premium of ₹0, indicating a neutral market response. There has been no movement in the GMP during the last three days. At the current GMP, shares will debut at the upper price band (₹129) with no listing gains.
| Date | GMP (₹) | Estimated Listing Price | Estimated Listing Gain | Trend |
| 21-01-2026 | ₹0 | ₹129 | 0% | Neutral |
| 20-01-2026 | ₹0 | ₹129 | 0% | – |
Note: The GMP figures are derived from informal market activity and are subject to change with shifts in demand, subscription trends, and market conditions.
Accretion Nutraveda IPO Reservation
The IPO allocation is divided among various investor categories as outlined below:
| Investor Category | Reservation |
| Market Maker Shares | 96,000 (5.00%) |
| QIB Shares | 9,08,000 (47.29%) |
| NII (HNI) Shares | 2,76,000 (14.37%) |
| Retail Shares | 6,40,000 (33.33%) |
| Total Shares | 19,20,000 (100.00%) |
Lot Size of the Accretion Nutraveda IPO
Bids can be made as per the prescribed lot sizes mentioned below:
| Investor Type | Lots | Shares | Amount |
| Individual Investors – Retail (Minimum) | 2 | 2,000 | ₹2,58,000 |
| Individual Investors – Retail (Maximum) | 2 | 2,000 | ₹2,58,000 |
| S-HNI (Minimum) | 3 | 3,000 | ₹3,87,000 |
| S-HNI (Maximum) | 7 | 7,000 | ₹9,03,000 |
| B-HNI (Minimum) | 8 | 8,000 | ₹10,32,000 |
Details of Accretion Nutraveda IPO Anchor Investors
Information on anchor investors participating in this IPO is given below:
| Particulars | Details |
| Anchor Bidding Date | January 27, 2026 |
| Shares Offered | Up to 5,44,800 |
| Portion Size | 60% of the QIB |
| 30 Days Lock-in for 50% shares | March 4, 2026 |
| 90 Days Lock-in for remaining shares | May 3, 2026 |
Accretion Nutraveda IPO Prospectus
Additional information regarding the IPO is given in these documents:
| Draft Red Herring Prospectus (DRHP) | |
| Red Herring Prospectus (RHP) | |
| Anchor Investors | – |
| Final Prospectus | Not Disclosed |
About Accretion Nutraveda
Accretion Nutraveda was founded in 2021. It is engaged in the manufacturing of Ayurveda and Nutraceutical products. Its offerings come in various forms like capsules, tablets, oral powders, and liquids. Mr. Mayur Popatlal Sojitra leads the company as the Managing Director, bringing over 12 years of experience in the pharma industry.
Accretion Nutraveda has established itself as a specialised contract manufacturer catering to Indian as well as international markets like the USA, Sri Lanka, and Singapore. The company operates in the fast-growing traditional healthcare space, competing with peers like Walpar Nutrition Limited and Influx Healthtech Limited.
| Issue Registrar | KFin Technologies Limited |
| Lead Manager | Sobhagya Capital Options Private Limited |
Objectives of the Accretion Nutraveda IPO
Capital raised from the issue will be utilised for the following purposes:
| S. No. | Particulars | Amount (in ₹ lakh) |
| 1. | Purchase of Automation Machinery | 421.66 |
| 2. | Machinery Purchase for New Manufacturing Setup | 803.23 |
| 3. | Working Capital Needs | 550.00 |
| 4. | General Corporate Purposes | – |
Strength Of Accretion Nutraveda
The following key strengths are the driving factors behind Accretion Nutraveda’s growth and performance:
- Experienced Leadership: The company is led by an experienced promoter and management group. They provide strategic direction, guide decision-making, and oversee day-to-day operations.
- Diverse Product Base: The company has a well-diversified portfolio of over 72 formulations across multiple dosage forms such as powders, tablets, capsules, and oral liquids.
- Quality Standards: The company maintains strict quality checks throughout the production process to ensure product safety and consistency.
- Long-Standing Relationships: Established relationships with suppliers and customers allow efficient supply chain management and repetition of business.
- Integrated Framework: The company follows an end-to-end operating model, beginning with raw material sourcing and continuing through to final product delivery. This makes the daily operations more efficient and provides scalability.
Risk of Accretion Nutraveda
Accretion Nutraveda’s business can be adversely affected by the following risk factors:
- Manufacturing Disruptions: The operations may be impacted by equipment failures, accidents, or natural events, which could lead to delays or shutdowns.
- Geographic Concentration: A majority of revenue comes from a few regions, increasing exposure to local economic or regulatory changes.
- Leased Facilities: Manufacturing units and offices are run on leased premises. Non-renewal or termination of leases could hamper operations, and relocation may be required.
- Cash Flow Pressure: Historical negative cash flows may limit flexibility in funding working capital and future expansion.
- Industry Demand Sensitivity: Revenue depends significantly on demand from the nutraceutical segment. Any shift in the industry trends may affect the revenue.
Accretion Nutraveda IPO Review
The Accretion Nutraveda IPO provides exposure for investors interested in the healthcare sector. The company has strong leadership, a wide product portfolio, and an integrated framework that improves its efficiency and scalability. However, the flat GMP, operational risks, and cash flow crunches indicate a cautious approach. The IPO may suit investors with a long-term horizon and higher risk tolerance, especially those comfortable with SME volatility.
Other Recent IPO List
If you found this IPO guide useful, you may also be interested in exploring these other IPOs:
| Digilogic Systems IPO | Shayona Engineering IPO |
| Aritas Vinyl IPO | Shadowfax Technologies IPO |
| Amagi Media Labs IPO | Armour Security India IPO |
| Narmadesh Brass Industries IPO | INDO SMC IPO |
Accretion Nutraveda IPO FAQs
The Accretion Nutraveda IPO is a book-built SME IPO aiming to raise up to ₹25 crore through a fresh issue of 19,20,000 equity shares, to be listed on the BSE SME.
You can apply through your broker or trading platform using the UPI or ASBA facility. Place your bids before the subscription period ends.
The IPO offers exposure to the Ayurveda and nutraceutical manufacturing space. However, it carries operational and cash flow risks. It is suitable for investors with a higher risk appetite and a long-term investment horizon.
As per the current GMP of ₹0, listing gains are not expected. After the debut, returns will depend on performance and investor demand.
The Accretion Nutraveda IPO will open on January 27, 2026, and close on January 30, 2026.
The lot size is 1,000 shares. Retail investors must apply for a minimum of 2 lots (2,000 shares), amounting to ₹2,58,000 at the upper price band.
The shares of Accretion Nutraveda IPO will be allotted on February 2, 2026.
The Accretion Nutraveda IPO is scheduled to list on the BSE SME on February 4, 2026.
